A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
Promising Hyperlipidemia Treatment Lowers Cardiovascular Risk miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.
RNA interference therapies safely lower atherosclerotic cholesterol healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.